Molecular-Targeted Drugs in Rheumatology
Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Tokyo Women's Medical University
2023-12-01
|
| Series: | Tokyo Women's Medical University Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en |
| _version_ | 1797376631205003264 |
|---|---|
| author | Eiichi Tanaka |
| author_facet | Eiichi Tanaka |
| author_sort | Eiichi Tanaka |
| collection | DOAJ |
| description | Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. |
| first_indexed | 2024-03-08T19:41:26Z |
| format | Article |
| id | doaj.art-5084a4e248ad4c1baba7559183723690 |
| institution | Directory Open Access Journal |
| issn | 2432-6186 |
| language | English |
| last_indexed | 2024-03-08T19:41:26Z |
| publishDate | 2023-12-01 |
| publisher | Society of Tokyo Women's Medical University |
| record_format | Article |
| series | Tokyo Women's Medical University Journal |
| spelling | doaj.art-5084a4e248ad4c1baba75591837236902023-12-25T06:02:01ZengSociety of Tokyo Women's Medical UniversityTokyo Women's Medical University Journal2432-61862023-12-0170213310.24488/twmuj.2023013twmujMolecular-Targeted Drugs in RheumatologyEiichi Tanaka0Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of MedicineCell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/enbiological disease-modifying anti-rheumatic drugsjanus kinase inhibitorsmolecular-targeted drugsrheumatoid arthritisrheumatic diseases |
| spellingShingle | Eiichi Tanaka Molecular-Targeted Drugs in Rheumatology Tokyo Women's Medical University Journal biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases |
| title | Molecular-Targeted Drugs in Rheumatology |
| title_full | Molecular-Targeted Drugs in Rheumatology |
| title_fullStr | Molecular-Targeted Drugs in Rheumatology |
| title_full_unstemmed | Molecular-Targeted Drugs in Rheumatology |
| title_short | Molecular-Targeted Drugs in Rheumatology |
| title_sort | molecular targeted drugs in rheumatology |
| topic | biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases |
| url | https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en |
| work_keys_str_mv | AT eiichitanaka moleculartargeteddrugsinrheumatology |